Citations

Clear

4847 citation(s) found for "Yu, Eric".

Prevalence and Outcomes in Patients Undergoing Reintubation After Anterior Cervical Spine Surgery: Results From the AOSpine North America Multicenter Study on 8887 Patients
Fehlings, Michael G. , Tetreault, Lindsay, Smith, Zachary A. , Hsu, Wellington K. , Tannoury, Chadi , Tannoury, Tony , Traynelis, Vincent C. , Mroz, Thomas E., Gokaslan, Ziya L. , Bydon, Mohamad , Giacomo, Anthony F. De, Jobse, Bruce C., Massicotte, Eric M. , Nagoshi, Narihito , Nakashima, Hiroaki , Gum, Jeffrey L. , Arnold, Paul M. , Mroz, Thomas E. , Riew, Kiehyun Daniel , Fehlings, Michael G , Tannoury, Chadi

Mayo Clinic

Global Spine Journal | April 19, 2017 | Volume: 7 | Issue: 1_suppl | Pages: 96S-102S

10.1177/2192568216687753 | PMID 28451501 Get It

Study Design: A multicenter, retrospective cohort study. Objective: To evaluate clinical outcomes in patients with reintubation after anterior cervical spine surgery. Methods: A total of 8887 patients undergoing anterior cervical spine surgery were enrolled in the AOSpine North America Rare Complications of Cervical Spine Surgery study. Patients with or without complications after surgery were included. Demographic and surgical information were collected for patients with reintubation. Patients were evaluated using a variety of assessment tools, including the modified Japanese Orthopedic Association scale, Nurick score, Neck Disability Index, and Short Form-36 Health Survey. Results: Nine cases of postoperative reintubation were identified. The total prevalence of this complication was 0.10% and ranged from 0% to 0.59% across participating institutions. The time to development of airway symptoms after surgery was within 24 hours in 6 patients and between 5 and 7 days in 3 patients. Although 8 patients recovered, 1 patient died. At final follow-up, patients with reintubation did not exhibit significant and meaningful improvements in pain, functional status, or quality of life. Conclusions: Although the prevalence of reintubation was very low, this complication was associated with adverse clinical outcomes. Clinicians should identify their high-risk patients and carefully observe them for up to 2 weeks after surgery.
Misplaced Cervical Screws Requiring Reoperation
Peterson, Jeremy , Smith, Zachary A. , Hsu, Wellington K. , Fehlings, Michael G. , Hart, Robert A. , Hilibrand, Alan S. , Rahman, RaʼKerry K., Tannoury, Chadi , Tannoury, Tony , Mroz, Thomas E. , Currier, Bradford L. , Giacomo, Anthony F. De, Fogelson, Jeremy L. , Jobse, Bruce C., Massicotte, Eric M. , Arnold, Paul M. , Nassr, Ahmad , Riew, Kiehyun Daniel , Fehlings, Michael G , Tannoury, Chadi

Mayo Clinic

Global Spine Journal | April 19, 2017 | Volume: 7 | Issue: 1_suppl | Pages: 46S-52S

10.1177/2192568216687527 | PMID 28451491 Get It

Study Design: A multicenter, retrospective case series. Objective: In the past several years, screw fixation of the cervical spine has become commonplace. For the most part, this is a safe, low-risk procedure. While rare, screw backout or misplaced screws can lead to morbidity and increased costs. We report our experiences with this uncommon complication. Methods: A multicenter, retrospective case series was undertaken at 23 institutions in the United States. Patients were included who underwent cervical spine surgery from January 1, 2005, to December 31, 2011, and had misplacement of screws requiring reoperation. Institutional review board approval was obtained at all participating institutions, and detailed records were sent to a central data center. Results: A total of 12 903 patients met the inclusion criteria and were analyzed. There were 11 instances of screw backout requiring reoperation, for an incidence of 0.085%. There were 7 posterior procedures. Importantly, there were no changes in the health-related quality-of-life metrics due to this complication. There were no new neurologic deficits; a patient most often presented with pain, and misplacement was diagnosed on plain X-ray or computed tomography scan. The most common location for screw backout was C6 (36%). Conclusions: This study represents the largest series to tabulate the incidence of misplacement of screws following cervical spine surgery, which led to revision procedures. The data suggest this is a rare event, despite the widespread use of cervical fixation. Patients suffering this complication can require revision, but do not usually suffer neurologic sequelae. These patients have increased cost of care. Meticulous technique and thorough knowledge of the relevant anatomy are the best means of preventing this complication.
Epidemiology and Outcomes of Vertebral Artery Injury in 16 582 Cervical Spine Surgery Patients: An AOSpine North America Multicenter Study
Hsu, Wellington K. , Kannan, Abhishek , Mai, Harry T., Fehlings, Michael G. , Smith, Zachary A. , Traynelis, Vincent C. , Gokaslan, Ziya L. , Hilibrand, Alan S. , Mroz, Thomas E., Bydon, Mohamad , Massicotte, Eric M. , Ray, Wilson Z. , Steinmetz, Michael P. , Smith, Gabriel A. , Pace, Jonathan , Corriveau, Mark, Lee, Sung‐Ho , Isaacs, Robert E., Wang, Jeffrey C. , Lord, Elizabeth L. , Buser, Zorica , Mai, Harry T., Nassr, Ahmad , Arnold, Paul M. , Mroz, Thomas E. , Riew, Kiehyun Daniel , Fehlings, Michael G

Mayo Clinic

Global Spine Journal | April 19, 2017 | Volume: 7 | Issue: 1_suppl | Pages: 21S-27S

10.1177/2192568216686753 | PMID 28451487 Get It

Study Design: A multicenter retrospective case series was compiled involving 21 medical institutions. Inclusion criteria included patients who underwent cervical spine surgery between 2005 and 2011 and who sustained a vertebral artery injury (VAI). Objective: To report the frequency, risk factors, outcomes, and management goals of VAI in patients who have undergone cervical spine surgery. Methods: Patients were evaluated on the basis of condition-specific functional status using the Neck Disability Index (NDI), modified Japanese Orthopaedic Association (mJOA) score, the Nurick scale, and the 36-Item Short-Form Health Survey (SF-36). Results: VAIs were identified in a total of 14 of 16 582 patients screened (8.4 per 10 000). The mean age of patients with VAI was 59 years (±10) with a female predominance (78.6%). Patient diagnoses included myelopathy, radiculopathy, cervical instability, and metastatic disease. VAI was associated with substantial blood loss (770 mL), although only 3 cases required transfusion. Of the 14 cases, 7 occurred with an anterior-only approach, 3 cases with posterior-only approach, and 4 during circumferential approach. Fifty percent of cases of VAI with available preoperative imaging revealed anomalous vessel anatomy during postoperative review. Average length of hospital stay was 10 days (±8). Notably, 13 of the 14 (92.86%) cases resolved without residual deficits. Compared to preoperative baseline NDI, Nurick, mJOA, and SF-36 scores for these patients, there were no observed changes after surgery ( P = .20-.94). Conclusions: Vertebral artery injuries are potentially catastrophic complications that can be sustained from anterior or posterior cervical spine approaches. The data from this study suggest that with proper steps to ensure hemostasis, patients recover function at a high rate and do not exhibit residual deficits.
Incidence and Outcomes of Acute Implant Extrusion Following Anterior Cervical Spine Surgery
Smith, Gabriel A. , Pace, Jonathan , Corriveau, Mark, Lee, Sung‐Ho , Mroz, Thomas E., Fehlings, Michael G. , Hart, Robert A. , Hilibrand, Alan S. , Bumpass, David B. , Gokaslan, Ziya L. , Bydon, Mohamad , Fogelson, Jeremy L. , Massicotte, Eric M. , Steinmetz, Michael P. , Mroz, Thomas E. , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Fehlings, Michael G

Mayo Clinic

Global Spine Journal | April 19, 2017 | Volume: 7 | Issue: 1_suppl | Pages: 40S-45S

10.1177/2192568216686752 | PMID 28451490 Get It

Study Design: Multi-institutional retrospective case series of 8887 patients who underwent anterior cervical spine surgery. Objective: Anterior decompression from discectomy or corpectomy is not without risk. Surgical morbidity ranges from 9% to 20% and is likely underreported. Little is known of the incidence and effects of rare complications on functional outcomes following anterior spinal surgery. In this retrospective review, we examined implant extrusions (IEs) following anterior cervical fusion. Methods: A retrospective multicenter case series study involving 21 high-volume surgical centers from the AOSpine North America Clinical Research Network. Medical records for 17 625 patients who received cervical spine surgery (levels from C2 to C7) between January 1, 2005, and December 31, 2011, were reviewed to identify occurrence of 21 predefined treatment complications. Results: Following anterior cervical fusion, the incidence of IE ranged from 0.0% to 0.8% across 21 institutions with 11 cases reported. All surgeries involved multiple levels, and 7/11 (64%) involved either multilevel corpectomies or hybrid constructs with at least one adjacent discectomy to a corpectomy. In 7/11 (64%) patients, constructs ended with reconstruction or stabilization at C7. Nine patients required surgery for repair and stabilization following IE. Average length of hospital stay after IE was 5.2 days. Only 2 (18%) had residual deficits after reoperation. Conclusions: IE is a very rare complication after anterior cervical spine surgery often requiring revision. Constructs requiring multilevel reconstruction, especially at the cervicothoracic junction, have a higher risk for failure, and surgeons should proceed with caution in using an anterior-only approach in these demanding cases. Surgeons can expect most patients to regain function after reoperation.
Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database
Renfro, Lindsay A. , Goldberg, Richard M. , Sobrero, Alberto , Adams, Richard , Seymour, Michel , Heinemann, Volker , Schmoll, Hans‐Joachim , Douillard, Jean‐Yves , Hurwitz, Herbert I. , Fuchs, Charles S. , Díaz‐Rubio, Eduardo , Porschen, Rainer, Tournigand, Christophe , Chibaudel, Benoist , Hoff, Paulo M. , Kabbinavar, Fairooz F. , Falcone, Alfredo , Punt, Cornelis J.A. , Hecht, J. Randolph, Souglakos, John , Bokemeyer, Carsten , Gramont, Aimery de , Seymour, Matthew T, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Tebbutt, Niall C. , van Cutsem, Eric, Saltz, Leonard, de Gramont, Aimery, Grothey, Axel , Cutsem, Eric Van , Saltz, Leonard B. , Sargent, Daniel J. , Falcone, Alfredo , Seymour, Matthew T , Adams, Richard , Schmoll, Hans-Joachim , Chibaudel, Benoist

Mayo Clinic

Journal of Clinical Oncology | April 17, 2017 | Volume: 35 | Issue: 17 | Pages: 1929-1937

10.1200/jco.2016.71.5771 | PMID 28414610 Get It

Purpose Factors contributing to early mortality after initiation of treatment of metastatic colorectal cancer are poorly understood. Materials and Methods Data from 22,654 patients enrolled in 28 randomized phase III trials contained in the ARCAD (Aide et Recherche en Cancérologie Digestive) database were pooled. Multivariable logistic regression models for 30-, 60-, and 90-day mortality were constructed, including clinically and statistically significant patient and disease factors and interaction terms. A calculator (nomogram) for 90-day mortality was developed and validated internally using bootstrapping methods and externally using a 10% random holdout sample from each trial. The impact of early progression on the likelihood of survival to 90 days was examined with time-dependent Cox proportional hazards models. Results Mortality rates were 1.4% at 30 days, 3.4% at 60 days, and 5.5% at 90 days. Among baseline factors, advanced age, lower body mass index, poorer performance status, increased number of metastatic sites, BRAF mutant status, and several laboratory parameters were associated with increased likelihood of early mortality. A multivariable model for 90-day mortality showed strong internal discrimination (C-index, 0.77) and good calibration across risk groups as well as accurate predictions in the external validation set, both overall and within patient subgroups. Conclusion A validated clinical nomogram has been developed to quantify the risk of early death for individual patients during initial treatment of metastatic colorectal cancer. This tool may be used for patient eligibility assessment or risk stratification in future clinical trials and to identify patients requiring more or less aggressive therapy and additional supportive measures during and after treatment.
Human-derived gut microbiota modulates colonic secretion in mice by regulating 5-HT3receptor expression via acetate production
Bhattarai, Yogesh , Schmidt, Bradley A., Larson, Eric D. , Grover, Madhusudan , Farrugia, Gianrico , Kashyap, Purna , Linden, David R. , Beyder, Arthur , Bhattarai, Y

Mayo Clinic

American Journal of Physiology-Gastrointestinal and Liver Physiology | April 14, 2017 | Volume: 313 | Issue: 1 | Pages: G80-G87

10.1152/ajpgi.00448.2016 | PMID 28408644 Get It

Serotonin [5-hydroxytryptamine (5-HT)], an important neurotransmitter and a paracrine messenger in the gastrointestinal tract, regulates intestinal secretion by its action primarily on 5-HT3and 5-HT4receptors. Recent studies highlight the role of gut microbiota in 5-HT biosynthesis. In this study, we determine whether human-derived gut microbiota affects host secretory response to 5-HT and 5-HT receptor expression. We used proximal colonic mucosa-submucosa preparation from age-matched Swiss Webster germ-free (GF) and humanized (HM; ex-GF colonized with human gut microbiota) mice. 5-HT evoked a significantly greater increase in short-circuit current (Δ Isc) in GF compared with HM mice. Additionally, 5-HT3receptor mRNA and protein expression was significantly higher in GF compared with HM mice. Ondansetron, a 5-HT3receptor antagonist, inhibited 5-HT-evoked Δ Iscin GF mice but not in HM mice. Furthermore, a 5-HT3receptor-selective agonist, 2-methyl-5-hydroxytryptamine hydrochloride, evoked a significantly higher Δ Iscin GF compared with HM mice. Immunohistochemistry in 5-HT3A-green fluorescent protein mice localized 5-HT3receptor expression to enterochromaffin cells in addition to nerve fibers. The significant difference in 5-HT-evoked Δ Iscbetween GF and HM mice persisted in the presence of tetrodotoxin (TTX) but was lost after ondansetron application in the presence of TTX. Application of acetate (10 mM) significantly lowered 5-HT3receptor mRNA in GF mouse colonoids. We conclude that host secretory response to 5-HT may be modulated by gut microbiota regulation of 5-HT3receptor expression via acetate production. Epithelial 5-HT3receptor may function as a mediator of gut microbiota-driven change in intestinal secretion.NEW & NOTEWORTHY We found that gut microbiota alters serotonin (5-HT)-evoked intestinal secretion in a 5-HT3receptor-dependent mechanism and gut microbiota metabolite acetate alters 5-HT3receptor expression in colonoids.View this article's corresponding video summary at https://www.youtube.com/watch?v=aOMYJMuLTcw&feature=youtu.be .
Pathogenic Variant in ACTB, p.Arg183Trp, Causes Juvenile-Onset Dystonia, Hearing Loss, and Developmental Delay without Midline Malformation
Conboy, Erin , Waggoner, Darrel, Das, Soma , Klee, Eric W. , Pichurin, Pavel N. , Vairo, Filippo, Pichurin, Pavel , Vairo, Filippo Pinto e , Ober, Carole , Dhamija, Radhika

Mayo Clinic

Case Reports in Genetics | April 12, 2017 | Volume: 2017 | Issue: No issue available | Pages: 1-4

10.1155/2017/9184265 | PMID 28487785 Get It

ACTB encodes the β-actin, and pathogenic variations in this gene have typically been associated with Baraitser-Winter cerebrofrontofacial syndrome, a congenital malformation syndrome characterized by short stature, craniofacial anomalies, and cerebral anomalies. Here, we describe the third case with the p.Arg183Trp variant in ACTB causing juvenile-onset dystonia. Our patient has severe, intractable dystonia, developmental delay, and sensorineural hearing loss, besides hyperintensities in the caudate nuclei and putamen on the brain MRI, which is a distinct but overlapping phenotype with the previously reported case of identical twins with the same alteration in ACTB.
Brain‐responsive neurostimulation in patients with medically intractable mesial temporal lobe epilepsy
Geller, Eric B., Skarpaas, Tara L. , Barkley, Gregory L., Bazil, Carl W., Berg, Michael J. van den, Bergey, Gregory K. , Cash, Sydney S. , Cole, Andrew J. , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, James, Fountain, Nathan B. , Goldman, Alicia, Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamar, Hirsch, Lawrence J. , Jobst, Barbara C. , King‐Stephens, David , Labar, Douglas, Leiphart, James W., Marsh, W. Richard , Meador, Kimford J. , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Shields, Donald C. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul C. Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Cicora, Kathy, Sun, Felice T., Morrell, Martha J. , Cole, Andrew J , Noe, Katherine H. , Gross, Robert E. , Goodman, Robert , Berg, Michael J., Edwards, Jonathan , Smith, Michael C. F. , Worrell, Gregory A. , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 11, 2017 | Volume: 58 | Issue: 6 | Pages: 994-1004

10.1111/epi.13740 | PMID 28398014 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of mesial temporal lobe (MTL) brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of mesial temporal lobe origin.MethodsSubjects with mesial temporal lobe epilepsy (MTLE) were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events.ResultsThere were 111 subjects with MTLE; 72% of subjects had bilateral MTL onsets and 28% had unilateral onsets. Subjects had one to four leads placed; only two leads could be connected to the device. Seventy‐six subjects had depth leads only, 29 had both depth and strip leads, and 6 had only strip leads. The mean follow‐up was 6.1 ± (standard deviation) 2.2 years. The median percent seizure reduction was 70% (last observation carried forward). Twenty‐nine percent of subjects experienced at least one seizure‐free period of 6 months or longer, and 15% experienced at least one seizure‐free period of 1 year or longer. There was no difference in seizure reduction in subjects with and without mesial temporal sclerosis (MTS), bilateral MTL onsets, prior resection, prior intracranial monitoring, and prior vagus nerve stimulation. In addition, seizure reduction was not dependent on the location of depth leads relative to the hippocampus. The most frequent serious device‐related adverse event was soft tissue implant‐site infection (overall rate, including events categorized as device‐related, uncertain, or not device‐related: 0.03 per implant year, which is not greater than with other neurostimulation devices).SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including patients with unilateral or bilateral MTLE who are not candidates for temporal lobectomy or who have failed a prior MTL resection.
Brain‐responsive neurostimulation in patients with medically intractable seizures arising from eloquent and other neocortical areas
Jobst, Barbara C. , Kapur, Ritu, Barkley, Gregory L., Bazil, Carl W., Berg, Michel J., Bergey, Gregory K. , Boggs, Jane , Cash, Sydney S. , Cole, Andrew J. , Duchowny, Michael , Duckrow, Robert B., Eisenschenk, Stephan, Fessler, A. James, Fountain, Nathan B. , Geller, Eric B., Gwinn, Ryder P. , Heck, Christianne, Herekar, Aamr A., Hirsch, Lawrence J. , King‐Stephens, David , Labar, Douglas, Marsh, W. Richard , Meador, Kimford J. , Miller, Ian , Mizrahi, Eli M., Murro, Anthony M., Nair, Dileep , Olejniczak, Piotr W., Park, Yong D., Rutecki, Paul , Salanova, Vicenta , Sheth, Raj D. , Skidmore, Christopher , Spencer, David , Srinivasan, Shraddha, Tatum, William O. , Ness, Paul Van, Vossler, David G. , Wharen, Robert E. , Yoshor, Daniel , Zimmerman, Richard S. , Skarpaas, Tara L. , Morrell, Martha J. , Noe, Katherine H. , Edwards, Jonathan C. W. , Goldman, Alica M. , Goodman, Robert , Gross, Robert E. , Smith, Michael C. F. , Worrell, Gregory A. , Cole, Andrew J , Fountain, Nathan , Hirsch, Lawrence J , Meador, Kimford J , Jobst, Barbara , Nair, Dileep R , Skidmore, Christopher , Morrell, Martha J

Mayo Clinic

Epilepsia | April 7, 2017 | Volume: 58 | Issue: 6 | Pages: 1005-1014

10.1111/epi.13739 | PMID 28387951 Get It

SummaryObjectiveEvaluate the seizure‐reduction response and safety of brain‐responsive stimulation in adults with medically intractable partial‐onset seizures of neocortical origin.MethodsPatients with partial seizures of neocortical origin were identified from prospective clinical trials of a brain‐responsive neurostimulator (RNS System, NeuroPace). The seizure reduction over years 2–6 postimplantation was calculated by assessing the seizure frequency compared to a preimplantation baseline. Safety was assessed based on reported adverse events. Additional analyses considered safety and seizure reduction according to lobe and functional area (e.g., eloquent cortex) of seizure onset.ResultsThere were 126 patients with seizures of neocortical onset. The average follow‐up was 6.1 implant years. The median percent seizure reduction was 70% in patients with frontal and parietal seizure onsets, 58% in those with temporal neocortical onsets, and 51% in those with multilobar onsets (last observation carried forward [LOCF] analysis). Twenty‐six percent of patients experienced at least one seizure‐free period of 6 months or longer and 14% experienced at least one seizure‐free period of 1 year or longer. Patients with lesions on magnetic resonance imaging (MRI; 77% reduction, LOCF) and those with normal MRI findings (45% reduction, LOCF) benefitted, although the treatment response was more robust in patients with an MRI lesion (p = 0.02, generalized estimating equation [GEE]). There were no differences in the seizure reduction in patients with and without prior epilepsy surgery or vagus nerve stimulation. Stimulation parameters used for treatment did not cause acute or chronic neurologic deficits, even in eloquent cortical areas. The rates of infection (0.017 per patient implant year) and perioperative hemorrhage (0.8%) were not greater than with other neurostimulation devices.SignificanceBrain‐responsive stimulation represents a safe and effective treatment option for patients with medically intractable epilepsy, including adults with seizures of neocortical onset, and those with onsets from eloquent cortex.